Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases

被引：48

作者：

Casu, Laura ^{[2
]}

Cottiglia, Filippo ^{[2
]}

Leonti, Marco ^{[2
]}

De Logu, Alessandro ^{[3
]}

Agus, Emanuela ^{[3
]}

Tse-Dinh, Yuk-Ching ^{[4
]}

Lombardo, Valentina ^{[1
]}

Sissi, Claudia ^{[1
]}

机构：

[1] Univ Padua, Dept Pharmaceut Sci, Padua, Italy

[2] Univ Cagliari, Dipartimento Farmaco Chim Tecnol, I-09124 Cagliari, Italy

[3] Univ Cagliari, Dipartimento Sci & Tecnol Biomed, Sez Microbiol Med, I-09124 Cagliari, Italy

[4] New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 23期

关键词：

Topoisomerase; Alkaloid; Anticancer; Antibacterial; Pancratium illyricum L; ANTICANCER DRUG DESIGN; AMARYLLIDACEAE ALKALOIDS; DNA TOPOISOMERASES; NATURAL-PRODUCTS; LYCORINE; CELLS; LYCOBETAINE; DERIVATIVES; BLOOD;

D O I：

10.1016/j.bmcl.2011.09.097

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

From the methanol extract of the bulbs of Pancratium illyricum L., three phenanthridine type alkaloids, ungeremine (1), (-)-lycorine (2) and (+)-vittatine (3) were isolated. For the evaluation of their anticancer and antibacterial potential, compounds 1-3 were tested against human (I, II alpha) and bacterial (IA, IV) topoisomerases. Our data demonstrated that ungeremine impairs the activity of both, human and bacterial topoisomerases. Remarkably, ungeremine was found to largely increments the DNA cleavage promoted by bacterial topoisomerase IA, a new target in antimicrobial chemotherapy. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：7041 / 7044

页数：4

共 50 条

[1] Effect of Gefitinib on the reactions of mammalian type I and type II DNA topoisomerases
Topcu, Zeki
Unlukurt, Ise
Zencir, Sevil
CANCER RESEARCH, 2010, 70
[2] Bacterial and archeal type I topoisomerases
Tse-Dinh, YC
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3): : 19 - 27
[3] Type II DNA topoisomerases as antibacterial targets
Shen, LL
Chu, DTW
CURRENT PHARMACEUTICAL DESIGN, 1996, 2 (02) : 195 - 208
[4] Bacterial type I topoisomerases - biological function and potential use as targets for antibiotic treatments
Szafran, Marcin
Zakrzewska-Czerwinska, Jolanta
Jakimowicz, Dagmara
POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2013, 67 : 130 - 142
[5] Type II and IB DNA topoisomerases as targets of anthracyclines
Capranico, G
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U229 - U230
[6] Type II topoisomerases as targets for rational drug design
Laponogov, I.
Veselkov, D.
Umrekar, T.
Crevel, I.
Pan, X.
Fisher, L.
Sanderson, M.
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C713 - C713
[7] Type II topoisomerases as targets for rational drug design
Laponogov, Ivan
Veselkov, Dennis A.
Umrekar, Trishant
Crevel, Isabelle M-T.
Pan, Xiao-Su
Selvarajah, Jogitha
Fisher, L. Mark
Sanderson, Mark R.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S74 - S74
[8] Recent Advances in the Inhibition of Bacterial Type II Topoisomerases
Bisacchi, Gregory S.
Dumas, Jacques
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 : 379 - 396
[9] POISONS OF TYPE-I AND TYPE-II DNA TOPOISOMERASES
CHARCOSSET, JY
SOUES, S
LAVAL, F
BULLETIN DU CANCER, 1993, 80 (11) : 923 - 954
[10] Type II DNA topoisomerases
Berger, JM
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1998, 8 (01) : 26 - 32

← 1 2 3 4 5 →